Preclinical optimization of Ly6E-targeted ADCs for increased durability and efficacy of anti-tumor response

• Main Authors: Josefa Dela Cruz Chuh (Author), MaryAnn Go (Author), Yvonne Chen (Author), Jun Guo (Author), Hanine Rafidi (Author), Danielle Mandikian (Author), Yonglian Sun (Author), Zhonghua Lin (Author), Kellen Schneider (Author), Pamela Zhang (Author), Rajesh Vij (Author), Danielle Sharpnack (Author), Pamela Chan (Author), Cecile de la Cruz (Author), Jack Sadowsky (Author), Dhaya Seshasayee (Author), James T. Koerber (Author), Thomas H. Pillow (Author), Gail D. Phillips (Author), Rebecca K Rowntree (Author), C. Andrew Boswell (Author), Katherine R. Kozak (Author), Andrew G. Polson (Author), Paul Polakis (Author), Shang-Fan Yu (Author), Peter S. Dragovich (Author), Nicholas J. Agard (Author)
• Format: Book
• Published: Taylor & Francis Group, 2021-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Early success with brentuximab vedotin in treating classical Hodgkin lymphoma spurred an influx of at least 20 monomethyl auristatin E (MMAE) antibody-drug conjugates (ADCs) into clinical trials. While three MMAE-ADCs have been approved, most of these conjugates are no longer being investigated in c...